KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Other Non Operating Income (2016 - 2025)

Boston Scientific's Other Non Operating Income history spans 17 years, with the latest figure at -$384.0 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income changed N/A year-over-year to -$384.0 million; the TTM value through Dec 2025 reached -$228.0 million, changed N/A, while the annual FY2025 figure was -$228.0 million, 1325.0% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$384.0 million at Boston Scientific, down from $68.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $181.0 million in Q3 2021 and bottomed at -$384.0 million in Q4 2025.
  • The 5-year median for Other Non Operating Income is -$14.0 million (2022), against an average of -$8.1 million.
  • The largest annual shift saw Other Non Operating Income soared 202.78% in 2021 before it tumbled 1800.0% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $26.0 million in 2021, then surged by 123.08% to $58.0 million in 2022, then plummeted by 124.14% to -$14.0 million in 2023, then skyrocketed by 114.29% to $2.0 million in 2024, then plummeted by 19300.0% to -$384.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Other Non Operating Income are -$384.0 million (Q4 2025), $68.0 million (Q3 2025), and $122.0 million (Q2 2025).